PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
PureTech's Founded Entity, Vedanta Biosciences, has expanded its leadership team with three key appointments. Christof Marré joins as SVP and Head of Commercial, bringing nearly 30 years of biopharma marketing experience. Dr. Steven Shiff becomes SVP of Clinical Research, leveraging his expertise as a gastroenterologist and clinical executive. Jack Kyte is promoted to SVP of Human Resources.
These appointments support Vedanta's ongoing Phase 2 COLLECTiVE202 trial of VE202 for ulcerative colitis and the pivotal Phase 3 RESTORATiVE303 trial of VE303 for C. difficile infection. The expanded leadership team will also focus on planning for commercial stage activities, signaling Vedanta's preparation for potential market entry.
L'ente fondato da PureTech, Vedanta Biosciences, ha ampliato il proprio team di leadership con tre nomine chiave. Christof Marré entra come SVP e Responsabile Commerciale, portando con sé quasi 30 anni di esperienza nel marketing biopharma. Il Dr. Steven Shiff diventa SVP della Ricerca Clinica, sfruttando la sua esperienza come gastroenterologo ed executive clinico. Jack Kyte è stato promosso a SVP delle Risorse Umane.
Queste nomine supportano il continuo studio COLLECTiVE202 di Fase 2 di VE202 per la colite ulcerosa e il decisivo studio RESTORATiVE303 di Fase 3 di VE303 per l'infezione da C. difficile. Il team di leadership ampliato si concentrerà anche sulla pianificazione delle attività nella fase commerciale, segnalando la preparazione di Vedanta per un potenziale ingresso nel mercato.
La entidad fundada por PureTech, Vedanta Biosciences, ha ampliado su equipo directivo con tres nombramientos clave. Christof Marré se une como SVP y Jefe Comercial, aportando casi 30 años de experiencia en marketing biopharma. El Dr. Steven Shiff se convierte en SVP de Investigación Clínica, aprovechando su experiencia como gastroenterólogo y ejecutivo clínico. Jack Kyte ha sido ascendido a SVP de Recursos Humanos.
Estos nombramientos apoyan el continuo estudio COLLECTiVE202 de Fase 2 de VE202 para la colitis ulcerosa y el estudio RESTORATiVE303 de Fase 3 de VE303 para la infección por C. difficile. El equipo de liderazgo ampliado también se centrará en la planificación de actividades comerciales, lo que señala la preparación de Vedanta para una posible entrada en el mercado.
PureTech가 설립한 Vedanta Biosciences가 3명의 핵심 인사를 영입하면서 리더십 팀을 확장했습니다. Christof Marré가 SVP이자 상업 부문 책임자로 합류하며, 거의 30년의 생화학 마케팅 경험을 제공합니다. Dr. Steven Shiff은 임상 연구의 SVP로 임명되며, 소화기내과 의사로서의 전문성과 임상 경험을 활용합니다. Jack Kyte는 인사 부문 SVP로 승진했습니다.
이번 인사는 VE202의 궤양성 대장염에 대한 2상 COLLECTiVE202 시험과 C. difficile 감염에 대한 3상 RESTORATiVE303 시험의 진행을 지원합니다. 확대된 리더십 팀은 상업 단계 활동 계획에도 집중할 것이며, 이는 Vedanta의 시장 진입 준비를 나타냅니다.
L'entité fondée par PureTech, Vedanta Biosciences, a élargi son équipe de direction avec trois nominations clés. Christof Marré rejoint en tant que SVP et Responsable Commercial, apportant près de 30 ans d'expérience en marketing biopharma. Le Dr. Steven Shiff devient SVP de la Recherche Clinique, tirant parti de son expertise en tant que gastro-entérologue et cadre clinique. Jack Kyte est promu SVP des Ressources Humaines.
Ces nominations soutiennent l'essai COLLECTiVE202 de Phase 2 de VE202 pour la colite ulcéreuse et l'essai clé RESTORATiVE303 de Phase 3 de VE303 pour l'infection à C. difficile. L'équipe de direction élargie se concentrera également sur la planification des activités commerciales, signalant la préparation de Vedanta pour une éventuelle entrée sur le marché.
Das von PureTech gegründete Unternehmen, Vedanta Biosciences, hat sein Führungsteam mit drei bedeutenden Ernennungen erweitert. Christof Marré tritt als SVP und Leiter des Commercial-Bereichs bei, er bringt fast 30 Jahre Erfahrung im Biopharma-Marketing mit. Dr. Steven Shiff wird SVP für Klinische Forschung und nutzt seine Expertise als Gastroenterologe und klinischer Führungskraft. Jack Kyte wird zum SVP für Personal befördert.
Diese Ernennungen unterstützen die laufende Phase 2 COLLECTiVE202 Studie von VE202 bei Colitis ulcerosa und die entscheidende Phase 3 RESTORATiVE303 Studie von VE303 bei C. difficile-Infektionen. Das erweiterte Führungsteam wird sich auch auf die Planung kommerzieller Aktivitäten konzentrieren, was auf Vedantas Vorbereitung für einen potenziellen Markteintritt hinweist.
- Expansion of leadership team with experienced professionals in key roles
- Progress in clinical trials: Phase 2 for ulcerative colitis and Phase 3 for C. difficile infection
- Preparation for commercial stage activities, indicating potential market entry
- None.
Appointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial stage activity
The full text of the announcement from Vedanta is as follows:
Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
Appointments support ongoing Phase 2 COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial of VE303 and planning for commercial stage activity
“I am delighted to welcome Christof and Steve to the team,” said Bernat Olle, Ph.D., Co-Founder and Chief Executive Officer of Vedanta Biosciences. “The expertise that Christof, Steve, and Jack bring are vital to our next phase of growth as we execute our ongoing pivotal Phase 3 RESTORATiVE303 trial of VE303 for C. difficile infection and Phase 2 COLLECTiVE202 trial of VE202 for ulcerative colitis, and establish our commercial function.”
Christof Marré brings almost three decades of experience as a biopharma marketing leader and strategist, and most recently served as VP of Marketing & Pipeline Planning at Alpine Immune Sciences, recently acquired by Vertex Pharmaceuticals. At Alpine, he established the company’s Commercial function, including building out capabilities in market research, competitive intelligence, healthcare practitioner marketing & patient advocacy, and driving indication prioritization and valuation within the company’s Immunology portfolio. Earlier in his career, Mr. Marré was involved with multiple successful product launches at both established and emerging biopharma companies. He holds a Master of Science degree in Economics from The London School of Economics and Political Science (LSE).
Steven Shiff, M.D., is a gastroenterologist and clinical executive with over 20 years of experience in research and industry R&D. Dr. Shiff was most recently SVP and Head of Clinical Development at Intercept Pharmaceuticals, where he oversaw design and implementation of the company’s global clinical development strategy focused on rare and serious liver diseases, including supporting an NDA filing. Previously, he served as VP, Clinical Development, and GI Therapeutic Area Head at Allergan for 14 years, in which capacity he led global clinical development of the company’s GI pipeline and marketed GI product portfolio. Dr. Shiff spent the first 13 years of his career as a practicing physician and professor, initially at The Rockefeller University and later at Rutgers-Robert Wood Johnson Medical School.
Jack Kyte has served as Vice President and Head of Human Resources at Vedanta since 2020, following more than a decade of multi-industry HR experience. Mr. Kyte is responsible for developing and executing Vedanta’s people strategy in alignment with the organization’s current and anticipated future needs and overseeing its human resources function both internally and with external partners.
About Vedanta Biosciences
Vedanta Biosciences is a clinical-stage biopharmaceutical company developing medicines for the treatment of gastrointestinal diseases. The company’s lead assets are potential first-in-class oral therapies – VE303, in a Phase 3 registrational trial for prevention of recurrent C. difficile infection, and VE202, in a Phase 2 trial for treatment of ulcerative colitis. Vedanta’s pipeline has been built using the company’s industry-leading product engine for the development of therapies based on defined consortia of bacteria grown from pure clonal cell banks. The product engine, supported by broad foundational intellectual property, includes one of the largest libraries of bacteria isolated from the human microbiome, vast clinical datasets, proprietary capabilities in consortium design, and end-to-end CGMP manufacturing capabilities at commercial launch scale.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both
For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to the VE303 and VE202 development programs, development plans and potential benefits to patients and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723091412/en/
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
puretech@fticonsulting.com
US Media
Nichole Bobbyn
+1 774 278 8273
nichole@tenbridgecommunications.com
Source: PureTech Health plc
FAQ
What new appointments did Vedanta Biosciences (PRTC) announce?
What clinical trials is Vedanta Biosciences (PRTC) currently conducting?
What is the significance of Vedanta Biosciences (PRTC) appointing a Head of Commercial?
What is Christof Marré's background in his new role at Vedanta Biosciences (PRTC)?
